Phase 3 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 50 years or older
- People whose study eye has been confirmed, through specific eye imaging tests, to have an active abnormal blood vessel growth beneath the central part of the retina, caused by wet age-related macular degeneration (wet AMD)
- People whose study eye has been confirmed, through a specific imaging test, to have no active abnormal "polyp-like" lesions (a related but distinct eye condition)
- People whose study eye has less than 50% of the affected area covered by scar tissue
- People whose study eye has a specific range of vision — roughly between 20/40 and 20/320 on a standard eye chart (confirm with trial site)
- People whose study eye has an affected area smaller than 12 times the size of the optic disc (a specific measurement used in eye imaging) (confirm with trial site)
- People who have received a full explanation of the trial and have signed a written consent form
Who may not be able to join:
- People who have previously received treatments for wet AMD in the study eye, such as photodynamic therapy or laser treatment (vitamin and supplement use is not a barrier)
- People who have previously received anti-VEGF injections (such as ranibizumab, bevacizumab, aflibercept, or similar medicines) in the study eye for wet AMD
- People whose study eye has scar tissue or fibrosis covering 50% or more of the affected area
- People whose study eye has had bleeding inside the eye within one month before the screening visit
- People whose study eye has an eye pressure of 25 mmHg or higher, including those with glaucoma where eye pressure remains at that level despite treatment
- People whose study eye has a total affected area greater than 12 optic-disc areas, as measured by a specific eye imaging test (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +82 2-3489-6298
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Best corrected visual acuity (BCVA) at Month 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.